Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $9.14M rose 50.7% year over year, behind the +58.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 51.7% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $394.31M (+1633.3%) for the fiscal year ending Dec 2026, a step up from the +53.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.14M+51.7% QoQ
- Last fiscal yearDec 2025
- $22.75M+53.0% YoY
- LTMMar 2026
- $26.76M+58.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 22.75M USD
- Year-over-year change
- +53.0%
- 4-year CAGR
- +31.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.75M | +53.0% |
| FY2024 | 2024-12-31 | 14.87M | +16.1% |
| FY2023 | 2023-12-31 | 12.81M | +22.8% |
| FY2022 | 2022-12-31 | 10.43M | +37.0% |
| FY2021 | 2021-12-31 | 7.61M | — |
Selling, General & Admin vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's LTM Mar 2026 selling, general & admin of $26.76M is the 9th highest of the 10 companies compared; the peer median is $79.08M.
- Its year-over-year change of +58.7% is the 2nd highest of 10, against a peer median of +18.8%.
- Over three fiscal years its annual growth of +29.7% compares with a peer median of +14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Mar 2026 | $467.04M | -17.3% | +2.0% | 21.4% | |
| LTM Jun 2026 | $351.33M | +8.3% | +2.1% | 34.8% | |
| LTM Jun 2026 | $91.25M | +50.5% | +35.3% | — | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Sep 2026 | $52.81M | +43.5% | +31.4% | — | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $26.76M | +58.7% | +29.7% | — | |
| LTM Mar 2026 | $22.56M | +1.9% | +16.6% | — | |
| Peer median (excluding CAPR) | $79.08M | +18.8% | +14.3% | 61.0% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 244.9K | 2.55M | 25.18M | 22.27M | 0 |
| Cost of Revenue | 0 | 21.82M | 36.45M | 49.97M | 0 |
| Gross Profit | 244.9K | (19.27M) | (11.27M) | (27.7M) | 0 |
| Gross Margin | 100.0% | -755.1% | -44.8% | -124.4% | — |
| Research & Development | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M |
| Selling, General & Admin | 7.61M | 10.43M | 12.81M | 14.87M | 22.75M |
| Operating Expenses | 21.18M | 10.43M | 12.81M | 14.87M | 108.14M |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| EBITDA | (19.78M) | (28.49M) | (21.22M) | (39.04M) | (100.11M) |
| EBITDA Margin | -8075.5% | -1116.5% | -84.3% | -175.3% | — |
| Operating Income | (20.94M) | (29.7M) | (24.08M) | (42.56M) | (108.14M) |
| Operating Margin | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Interest Income | 0 | 521.53K | 1.73M | 2.2M | 6.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.05M |
| Other Income / Expenses | 915.92K | 677.85K | 1.79M | 2.1M | 3.1M |
| Income Before Tax | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Pre-Tax Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Net Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (Basic) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| EPS (Diluted) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| Weighted Avg Shares | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
| Weighted Avg Shares (Diluted) | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.